Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
Toyoaki Hida, Hiroshi Nokihara, Masashi Kondo et al. · The Lancet · 2017
Cited by 911 works. doi:10.1016/s0140-6736(17)30565-2
Authors
- Toyoaki Hida
- Hiroshi Nokihara
- Masashi Kondo
- Young Hak Kim
- Koichi Azuma
- Takashi Seto
- Yuichi Takiguchi
- Makoto Nishio
- Hiroshige Yoshioka
- Fumio Imamura
- Katsuyuki Hotta
- Satoshi Watanabe
- Kōichi Goto
- Miyako Satouchi
- Toshiyuki Kozuki
- Takehito Shukuya
- Kazuhiko Nakagawa
- Tetsuya Mitsudomi
- Nobuyuki Yamamoto
References
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
- Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
- Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
- First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
- Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors
- CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib
- Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study
- Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study
- Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
- CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study